P687: A PHASE 1 STUDY WITH THE NOVEL B-CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB-11417 AS MONOTHERAPY OR IN COMBINATION WITH ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH B-CELL MALIGNANCIES: PRELIMINARY DATA

• S. Opat,
• C. Y. Cheah,
• M. Lasica,
• E. Verner,
• P. J. Browett,
• H. Chan,
• J. D. Soumerai,
• E. González Barca,
• J. Hilger,
• Y. Fang,
• J. Huang,
• D. Simpson,
• C. S. Tam

Affiliations

S. Opat

1 Monash Health, Clayton

C. Y. Cheah

3 Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Nedlands

M. Lasica

6 St. Vincent’s Hospital Melbourne, Fitzroy, Victoria

E. Verner

7 Concord Repatriation General Hospital, Concord

P. J. Browett

9 Auckland City Hospital

H. Chan

10 North Shore Hospital, Auckland, New Zealand

J. D. Soumerai

11 Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, United States of America

E. González Barca

12 Institut Català d’Oncologia-Hospitalet, IDIBELL, Universitat de-Barcelona, Barcelona, Spain

J. Hilger

13 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America

Y. Fang

13 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America

J. Huang

13 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America

D. Simpson

13 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America

C. S. Tam

14 Peter MacCallum Cancer Centre, Melbourne